Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT02197572 Completed - Clinical trials for Advanced Solid Tumors

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Start date: September 15, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the effect of a single dose of 40 mg sapanisertib (MLN0128) on the electrocardiographic QT/QTc interval in participants with advanced solid tumors.

NCT ID: NCT02179918 Completed - Clinical trials for Advanced Solid Tumors

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Start date: August 2014
Phase: Phase 1
Study type: Interventional

This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the Recommended Phase 2 Dose (RP2D) of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in combination with MK-3475, a PD-1 inhibitor in patients with solid tumors.

NCT ID: NCT02134067 Terminated - Clinical trials for Advanced Solid Tumors

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of TAS-119 and determine the most appropriate dose in combination with Paclitaxel for subsequent studies in patients with advanced solid tumors. TAS-119 is a novel, selective Aurora A kinase inhibitor, which has previously been demonstrated to enhance the activity of paclitaxel in preclinical studies

NCT ID: NCT02122770 Completed - Clinical trials for Advanced Solid Tumors

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

Start date: April 1, 2014
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose administration of itraconazole on the single-dose IV PK of MLN4924.

NCT ID: NCT02110355 Completed - Cancer Clinical Trials

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Start date: December 19, 2014
Phase: Phase 1
Study type: Interventional

Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.

NCT ID: NCT02057380 Completed - Clinical trials for Advanced Solid Tumors

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Start date: April 16, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.

NCT ID: NCT02040558 Terminated - Clinical trials for Advanced Solid Tumors

Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors

Start date: July 2013
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, dose escalation study of MNK-010 in subjects with advanced solid malignancies who have failed conventional therapy. The safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of ascending doses of MNK-010 will be evaluated in subjects with advanced solid tumors.

NCT ID: NCT02031055 Completed - Clinical trials for Advanced Solid Tumors

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Start date: February 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate, in patients with advanced solid tumors, the mass balance of FTD and TPI after a single dose of TAS-102 with a light tracer dose of [14C]FTD or [14C]TPI.

NCT ID: NCT01999972 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Start date: February 26, 2014
Phase: Phase 1
Study type: Interventional

Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually develop evasive resistance. It is proposed that mesenchymal-epithelial transition factor (c-MET) and its ligand hepatocyte growth factor (HGF or scatter factor) contribute to VEGF inhibitor resistance, such that combining a c-MET inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF inhibitor alone. This hypothesis will be tested using the cMET/ALK inhibitor, crizotinib, in combination with the VEGF inhibitor, axitinib.Since this will be the first study of axitinib given in combination with crizotinib, the study will primarily assess the safety and tolerability of the combination regimen.

NCT ID: NCT01992341 Completed - Clinical trials for Advanced Solid Tumors

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Start date: July 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel